Literature DB >> 33318307

Detection of NUCB2/nesfatin-1 in cerebrospinal fluid of multiple sclerosis patients.

Masaru Shimizu1,2,3, Taizo Manome3, Masumi Kumami3, Kouzou Matsumura3, Kazuaki Kanai2, Kenju Shimomura1, Yuko Maejima1.   

Abstract

NUCB2/nesfatin-1 was originally discovered as an anorexigenic peptide. However, recent studies revealed various additional functions including the regulation of inflammation. However, there are no studies that investigated the involvement of NUCB2/nesfatin-1 in neuroinflammatory diseases. Here, we aimed to investigate the involvement of NUCB2/nesfatin-1 in a representative neuroinflammatory disease, multiple sclerosis (MS). Cerebrospinal fluids (CSF) were collected from 24 MS patients and 10 control subjects and NUCB2/nesfatin-1, proinflammatory cytokines (TNF-α, IL-1β) and anti-inflammatory cytokines (IL-10, TGF-β) levels were measured by using ELISA assay. Also the expression of NUCB2/nesfatin-1 in the CSF of MS patient was investigated by western blot analysis. Expression of NUCB2/nesfatin-1 was confirmed in the CSF of the MS patient by western blot analysis. NUCB2/nesfatin-1 levels were significantly higher in the CSF of the MS patients. Among the measured cytokines, only IL-1β was lower in the CSF of the MS patients. We report for the first time increased NUCB2/nesfatin-1 levels in the CSF of MS patients.

Entities:  

Keywords:  NUCB2/nesfatin-1; inflammation; multiple sclerosis

Mesh:

Substances:

Year:  2020        PMID: 33318307      PMCID: PMC7762516          DOI: 10.18632/aging.202287

Source DB:  PubMed          Journal:  Aging (Albany NY)        ISSN: 1945-4589            Impact factor:   5.682


  22 in total

1.  Delayed treatment of MS is associated with high CSF levels of IL-6 and IL-8 and worse future disease course.

Authors:  Mario Stampanoni Bassi; Ennio Iezzi; Doriana Landi; Fabrizia Monteleone; Luana Gilio; Ilaria Simonelli; Alessandra Musella; Georgia Mandolesi; Francesca De Vito; Roberto Furlan; Annamaria Finardi; Girolama A Marfia; Diego Centonze; Fabio Buttari
Journal:  J Neurol       Date:  2018-08-28       Impact factor: 4.849

2.  Interleukin-6 concentration in serum and cerebrospinal fluid in multiple sclerosis patients.

Authors:  Z Stelmasiak; M Kozioł-Montewka; B Dobosz; K Rejdak; H Bartosik-Psujek; K Mitosek-Szewczyk; E Belniak-Legieć
Journal:  Med Sci Monit       Date:  2000 Nov-Dec

3.  A novel adipocytokine, nesfatin-1 modulates peripheral arterial contractility and blood pressure in rats.

Authors:  Hideyuki Yamawaki; Minako Takahashi; Masashi Mukohda; Tomoka Morita; Muneyoshi Okada; Yukio Hara
Journal:  Biochem Biophys Res Commun       Date:  2012-01-24       Impact factor: 3.575

4.  The novel function of nesfatin-1 as an anti-inflammatory and antiapoptotic peptide in subarachnoid hemorrhage-induced oxidative brain damage in rats.

Authors:  Derya Özsavcí; Mehmet Erşahin; Azize Şener; Özlem Bingol Özakpinar; Hale Z Toklu; Dilek Akakín; Göksel Şener; Berrak Ç Yeğen
Journal:  Neurosurgery       Date:  2011-06       Impact factor: 4.654

5.  Nesfatin-1-regulated oxytocinergic signaling in the paraventricular nucleus causes anorexia through a leptin-independent melanocortin pathway.

Authors:  Yuko Maejima; Udval Sedbazar; Shigetomo Suyama; Daisuke Kohno; Tatsushi Onaka; Eisuke Takano; Natsu Yoshida; Masato Koike; Yasuo Uchiyama; Ken Fujiwara; Takashi Yashiro; Tamas L Horvath; Marcelo O Dietrich; Shigeyasu Tanaka; Katsuya Dezaki; Shinsuke Oh-I; Koushi Hashimoto; Hiroyuki Shimizu; Masanori Nakata; Masatomo Mori; Toshihiko Yada
Journal:  Cell Metab       Date:  2009-11       Impact factor: 27.287

6.  Nesfatin-1 attenuates injury in a rat model of myocardial infarction by targeting autophagy, inflammation, and apoptosis.

Authors:  Maryam Naseroleslami; Masuomeh Sharifi; Kamran Rakhshan; Behnaz Mokhtari; Nahid Aboutaleb
Journal:  Arch Physiol Biochem       Date:  2020-08-07       Impact factor: 4.076

7.  The anti-inflammatory and anti-apoptotic effects of nesfatin-1 in the traumatic rat brain.

Authors:  Chong-Hui Tang; Xiao-Jun Fu; Xin-Long Xu; Xiao-Jie Wei; Hong-Song Pan
Journal:  Peptides       Date:  2012-04-24       Impact factor: 3.750

8.  Nesfatin-1 as a novel cardiac peptide: identification, functional characterization, and protection against ischemia/reperfusion injury.

Authors:  T Angelone; E Filice; T Pasqua; N Amodio; M Galluccio; G Montesanti; A M Quintieri; M C Cerra
Journal:  Cell Mol Life Sci       Date:  2012-09-07       Impact factor: 9.261

9.  Stressor-responsive central nesfatin-1 activates corticotropin-releasing hormone, noradrenaline and serotonin neurons and evokes hypothalamic-pituitary-adrenal axis.

Authors:  Natsu Yoshida; Yuko Maejima; Udval Sedbazar; Akihiko Ando; Hideharu Kurita; Boldbaatar Damdindorj; Eisuke Takano; Darambazar Gantulga; Yusaku Iwasaki; Tomoyuki Kurashina; Tatsushi Onaka; Katsuya Dezaki; Masanori Nakata; Masatomo Mori; Toshihiko Yada
Journal:  Aging (Albany NY)       Date:  2010-11       Impact factor: 5.682

10.  Cerebrospinal fluid detection of interleukin-1β in phase of remission predicts disease progression in multiple sclerosis.

Authors:  Silvia Rossi; Valeria Studer; Caterina Motta; Giorgio Germani; Giulia Macchiarulo; Fabio Buttari; Raffaele Mancino; Maura Castelli; Valentina De Chiara; Sagit Weiss; Gianvito Martino; Roberto Furlan; Diego Centonze
Journal:  J Neuroinflammation       Date:  2014-02-18       Impact factor: 8.322

View more
  2 in total

1.  Elevated Nesfatin-1 Level in Synovium and Synovial Fluid is Associated with Pro-Inflammatory Cytokines in Patients with Rheumatoid Arthritis.

Authors:  Shuo Zhang; Genxiang Rong; Yayun Xu; Juehua Jing
Journal:  Int J Gen Med       Date:  2021-09-07

2.  Tear proteomics reveals the molecular basis of the efficacy of human recombinant nerve growth factor treatment for Neurotrophic Keratopathy.

Authors:  Damiana Pieragostino; Manuela Lanzini; Ilaria Cicalini; Maria Concetta Cufaro; Verena Damiani; Leonardo Mastropasqua; Vincenzo De Laurenzi; Mario Nubile; Paola Lanuti; Giuseppina Bologna; Luca Agnifili; Piero Del Boccio
Journal:  Sci Rep       Date:  2022-01-24       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.